Study Details

Back
Study ID 2215-CL-0101
Study Title A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia.
Clinicaltrials.gov Identifier NCT02014558
Compound Name ASP2215 / gilteritinib fumarate
Medical Indication or Disease Acute myeloid leukemia
Study Sponsor Astellas Pharma Global Development, Inc.
Collaborator Not Applicable
Study Start Date 09-Oct-2013
Study Completion Date 07-Mar-2018
Clinical Study Result
Select the language
English
Plain Language Summary
Select the language
English

QUICK SEARCH

USEFUL LINKS